A novel class of kappa opioid receptor (KOR) ligands


The invention describes a novel class of kappa opioid receptor (KOR) ligands which can be used for the therapy of a variety of human disorders

Category

Life sciences

Projectnumber

P1408247

Patent Status

US-Application: priority date March 30, 2015
Owner: University of Innsbruck

Description

The invention describes a novel class of kappa opioid receptor (KOR) ligands which can be used for the therapy of a variety of human disordersApplication

Application

Novel drugs interacting with the KOR for the treatment of:

  • Pain
  • Psychiatric disorders: dysphoria, depression, bipo-lar disorders, mood disorders, anxiety spectrum disorders (stress, phobias, panic)
  • Psychotic disorders: schizophrenia
  • Neurological disorders
  • Neurodegenerative diseases: Alzheimer´s dis-ease, Parkinson´s disease
  • Addiction: drug and behavioral addiction
  • Eating disorders: obesity, overweight
  • Epilepsy
  • Inflammatory diseases: Crohn´s disease, ulcera-tive colitis, irritable bowel Syndrome
  • Itching: Pruritus
  • Water retention: oliguria, edemas

Benefits

  • The new class of KOR ligands is synthetically readily accessible and cost-effective to prepare.
  • The KOR agonists show high efficacy in an animal model of visceral pain, while the partial agonists were also active but with lower potency.
  • No signs of sedation and motor impairment are detected.

Cooperation Options

License agreement

Contact

Dr. Angela Siegling
Schutzrechtsmanagement
+ 43 1 501 75 - 552